CK 101

Drug Profile

CK 101

Alternative Names: CK-101; Covalent 3rd generation EGFR inhibitors - Fortress Biotech/NeuPharma; Irreversible third generation EGFR inhibitors - Fortress Biotech/NeuPharma; RX-518

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Suzhou NeuPharma
  • Developer Checkpoint Therapeutics
  • Class Antibodies; Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 11 Sep 2017 CK 101 receives Orphan Drug status for Non-small cell lung cancer in USA
  • 01 Apr 2017 Interim pharmacodynamic data from preclinical study in Non small cell lung cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 17 Mar 2017 Checkpoint Therapeutics has patents pending CK 101 and related compounds, in Canada, Europe, USA and World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top